PARP1 and cancer: These results suggested that p-Tyr19-CDK9 mediated by ALK is clinically relevant in cancer patients and supports p-ALK–p-Tyr19-CDK9 possibly being potential biomarkers for HR activity and predicting tumor resistance to PARP inhibitors.